D.E. Shaw & Co
EWTX icon

D.E. Shaw & Co’s Edgewise Therapeutics EWTX Stock Holding History

D.E. Shaw & Co’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.68M Buy
189,115
+84,252
+80% +$2.9M ﹤0.01% 2049
2026
Q1 		$3.3M Sell
104,863
-289,832
-73% -$8.36M ﹤0.01% 2505
2025
Q4 		$9.79M Sell
394,695
-282,866
-42% -$5.68M 0.01% 1773
2025
Q3 		$11M Buy
677,561
+82,129
+14% +$1.16M 0.01% 1603
2025
Q2 		$7.81M Buy
595,432
+454,884
+324% +$6.56M 0.01% 1685
2025
Q1 		$3.09M Sell
140,548
-545,823
-80% -$14.3M ﹤0.01% 2273
2024
Q4 		$18.3M Buy
686,371
+231,023
+51% +$7.36M 0.01% 1084
2024
Q3 		$12.2M Buy
455,348
+143,872
+46% +$2.86M 0.01% 1289
2024
Q2 		$5.61M Sell
311,476
-162,204
-34% -$2.83M 0.01% 1760
2024
Q1 		$8.64M Buy
473,680
+441,730
+1,383% +$7.02M 0.01% 1473
2023
Q4 		$350K Buy
+31,950
New +$224K ﹤0.01% 3681
2023
Q2 		– Sell
-24,736
Closed -$165K – 4324
2023
Q1 		$165K Buy
24,736
+13,462
+119% +$125K ﹤0.01% 3940
2022
Q4 		$101K Buy
+11,274
New +$106K ﹤0.01% 4362
2021
Q4 		– Sell
-13,695
Closed -$227K – 5489
2021
Q3 		$227K Sell
13,695
-32,472
-70% -$587K ﹤0.01% 4508
2021
Q2 		$985K Buy
+46,167
New +$1.26M ﹤0.01% 3555

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co's EWTX Position: Q2 2026 in Review

D.E. Shaw & Co increased its Edgewise Therapeutics (EWTX) stake by 80% in Q2 2026, buying an estimated $2.9M and bringing the position to 189,115 shares worth $7.68M. The position accounts for ﹤0.01% of the portfolio, ranked #2049.

D.E. Shaw & Co first reported a position in EWTX in Q2 2021 and has held it in 15 quarters since. The position peaked at $18.3M in Q4 2024. 225 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • D.E. Shaw & Co held 189,115 shares of Edgewise Therapeutics worth $7.68M as of Q2 2026.
  • D.E. Shaw & Co bought 84,252 Edgewise Therapeutics shares in Q2 2026, an estimated $2.9M.
  • Edgewise Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #2049 holding.
  • D.E. Shaw & Co first reported a position in Edgewise Therapeutics in Q2 2021 and has held it in 15 quarters since.
  • D.E. Shaw & Co's Edgewise Therapeutics position peaked at $18.3M in Q4 2024.
  • 225 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.